RT Journal Article
SR Electronic
T1 SARS-CoV-2 IgG antibody responses in rt-PCR positive cases: first report from India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.13.20229716
DO 10.1101/2020.11.13.20229716
A1 Dash, Girish Chandra
A1 Parai, Debaprasad
A1 Choudhary, Hari Ram
A1 Peter, Annalisha
A1 Rout, Usha Kiran
A1 Nanda, Rashmi Ranjan
A1 Kshatri, Jaya Singh
A1 Kanungo, Srikanta
A1 Palo, Subrata Kumar
A1 Pati, Sanghamitra
A1 Bhattacharya, Debdutta
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.11.13.20229716.abstract
AB The SARS-CoV-2 antibody responses remain poorly understood and the clinical utility of serological testing is still unclear. As it is thought to confer some degree of immunity, this study is carried out to know the relationship between demographics and ct value of confirmed rt-PCR patients. A total of 384 serum samples were collected between 4-6 weeks after confirmed SARS-CoV-2 infection. IgG positivity was found to be 80.2% (95% CI, 76.2 – 84.2). The IgG positivity increased with the decrease in the ct value, with highest of 87.6% positivity in individuals with <20 ct value. The mean (± SD) ct value of IgG positives and og IgG negatives was 23.34 (± 6.09) and 26.72 (± 7.031) respectively. There was no significant difference found between the demographic characteristics such as age, sex, symptoms and antibody response. The current study is first of its kind wherein we have assessed the correlation of ct of RT-PCR with development of IgG against SARS-CoV-2. Our study showed that although Ct value might not have any relation with severity of the diseases but is associated with the antibody response among the SARS-CoV-2 infected individual.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was carried out with intramural funding support from Indian Council of Medical Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethical Committee of ICMR-Regional Medical Research CentreAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available from Corresponding Author on genuine request